BioInfra
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
BioInfra is a contract research organization (CRO), a company that runs clinical and laboratory tests on behalf of pharmaceutical firms rather than developing its own drugs.
It provides services including bioequivalence testing for generic medicines, early-phase clinical trials for improved drugs, full regulatory clinical trials across all phases, immunoassay analysis for large-molecule biologics, and finished-drug quality testing. Listed on KOSDAQ, Korea's tech and small-cap board, it operates across four specialized divisions, each focused on a distinct stage of the drug-development and quality-assurance process.
Summary is AI-generated and may contain errors · figures from DART filings
BioInfra in five facts
What does BioInfra do?
BioInfra is a contract research organization (CRO), a company that runs clinical and laboratory tests on behalf of pharmaceutical firms rather than developing its own drugs.
Where is BioInfra listed and in which sector?
BioInfra (Korean name: 바이오인프라) trades under KRX code 199730 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Biotechnology.
How large is BioInfra?
Its market capitalisation was US$7.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- DisclosureOct 14
- Report on securities held by executives/major shareholdersOct 12
- Other market noticeOct 7
- Other market notice (delisting risk notice: market cap below threshold)Sep 30
- Other market notice (delisting risk notice: market cap below threshold)Sep 21
- [Attachment amended] Material event report (merger)M&A · Sep 15
- Shareholder register closure / record date setSep 8
- Material event report (merger)M&A · Sep 8
- Operating results (preliminary) (fair disclosure)
BioInfra filed provisional (unaudited) separate results for Q2 2026: revenue of US$5.88M (+42.5% year on year), operating profit of US$154K (from a loss a year earlier) and net income of US$103K (from a loss a year earlier).
Earnings · Jul 24 - Cash/in-kind dividend decision
BioInfra declared a cash dividend of US$0.20 per share, equal to about 6.26% of the recent share price.
Dividend · Mar 10 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 29